What’s moving
Signals we’re watching this quarter
In-licensing and distribution deals are reshaping who reaches patients first in each market.
CDMO and fill-finish capacity expansions are shifting where manufacturing bottlenecks actually sit.
Reimbursement and market-access rules are diverging further across ASEAN markets, complicating launch sequencing.
How FZ Solution helps
Five modules, applied to healthcare
Market sizing & forecasting
Forecast demand by therapeutic area and market, accounting for access and reimbursement dynamics.
Competitor tracking
Monitor approvals, launches, and licensing announcements as they are filed.
Partner search & validation
Score potential licensing, distribution, and CDMO partners against regulatory and delivery-risk criteria.
Due diligence
Run explainable anomaly checks on licensing or M&A targets ahead of board and regulatory review.
Customer insight
Track prescriber and patient-access patterns beyond claims data alone, market by market.
Sample output
What a signal looks like
NMPA grants priority review to three oncology assets from regional developers this quarter.
FZ Solution maps which in-market licensing partners are best positioned to move first.
Book a healthcare briefing
See a live signal feed for healthcare in a 20-minute walkthrough.